LE 135 - Moligand™, ≥97%(HPLC) , CAS No.155877-83-1

CAS: 155877-83-1 Cat. No.: L287663 分子式: C29H30N2O2 分子量: 438.56 EC番号: 806-164-7
注文可能
グレード&純度 Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. ≥97%(HPLC)
Synonyms
4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid|LE135|LE-135|ST 24:1;O2;T|4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,4]benzodiazepin-13-yl)benzoic acid|4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-5,12-diaza-benzo[4,5]cyclohepta[1,2-b]naphthalen-13-yl)-benzoic acid|4-(7,8,9,10-TETRAHYDRO-5,7,7,10,10-PENTAMETHYL-5H-BENZO[E]NAPHTHO[2,3-B][1,4]DIAZEPIN-13-YL)BENZOIC ACID|LE 135|H-Ala(Cl)-OH|4-(5H-7,8,9,10-tetrahydro-5,7,7,10,10-pentamethylbenzo(e)naphtho(2,3-b)(1,4)diazepin-13-yl)benzoic acid|4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoicacid|Malic acid, 2-methyl-
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
サイズ
USA
ドイツ (EU)*
価格
個数
5mg
L287663-5mg
3 在庫あり
—

$104.90

$157.90
保存 $53.00 (33.57%)
10mg
L287663-10mg
2 在庫あり
—

$176.90

$265.90
保存 $89.00 (33.47%)
25mg
L287663-25mg
1 在庫あり
—

$316.90

$475.90
保存 $159.00 (33.41%)
50mg
L287663-50mg
1 在庫あり
—

$475.90

$713.90
保存 $238.00 (33.34%)
100mg
L287663-100mg
1 在庫あり
—

$854.90

$1,282.90
保存 $428.00 (33.36%)
Enter a quantity for the sizes you want to add.

概要

Application:

LE 135 has been used for in vitro islet treatment.

仕様

同義語
4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-benzo[e]naphtho[2,3-b][1,4]diazepin-13-yl)benzoic acid | LE135 | LE-135 | ST 24:1;O2;T | 4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,4]benzodiazepin-13-yl)benzoic acid | 4-(5,7,7,10,10-Pentamethyl-7,8,9,10-tetrahydro-5H-5,12-diaza-benzo[4,5]cyclohepta[1,2-b]naphthalen-13-yl)-ben もっと見る
仕様と純度
Moligand™, ≥97%(HPLC)
生化学的・生理学的メカニズム
Retinoic acid antagonist; displays moderate selectivity for RARβover RARα(Kivalues are 0.22 and 1.4μM respectively). Highly selective over RARγand RXRα. Inhibits human HL-60 leukemia cell differentiation induced by Am80 (IC50= 150 nM).LE135 is a retinoic acid receptor (RAR) antagonist with selectivity for RARβ (Ki = 220 nM) over RARα (Ki = 1.4 μM). LE135 inhibits retinoic acid-induced transcriptional activation of RARβ (>70% inhibition at 10 μM), but not RARα, RARγ or retinoid X receptor α (RXRα). There is high interest in retinoic acid receptors for cancer and for differentiation studies. LE135 has been shown to inhibit retinoid Am80-induced differentiation of human promyelocytic leukemia HL-60 cells with an IC50 value of 0.2 μM. LE135 has been used to study the role of a retinoic acid receptor-β (RARβ) on the differentiation of mesenchymal stem cells, and was found to inhibit the neuronal differentiation promoting effects of all-trans retinoic acid (ATRA) on mesenchymal stem cells.
保管条件
Store at -20°C
入荷
Ice chest + Ice pads
この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。
等級
Moligand™
アクションタイプ
ACTIVATOR
純度
≥97%(HPLC)
名前と識別子
パブケム・シド
パブケム・シド・ウル
https://pubchem.ncbi.nlm.nih.gov/substance/488196651
SMILES
CC1(CCC(C2=CC3=C(C=C21)N=C(C4=CC=CC=C4N3C)C5=CC=C(C=C5)C(=O)O)(C)C)C
IUPAC Name
4-(5,7,7,10,10-pentamethyl-8,9-dihydronaphtho[2,3-b][1,4]benzodiazepin-13-yl)benzoic acid
InChIKey
YZZAIQOVMHVWBS-UHFFFAOYSA-N
InChI
1S/C29H30N2O2/c1-28(2)14-15-29(3,4)22-17-25-23(16-21(22)28)30-26(18-10-12-19(13-11-18)27(32)33)20-8-6-7-9-24(20)31(25)5/h6-13,16-17H,14-15H2,1-5H3,(H,32,33)
異性体SMILES
CC1(CCC(C2=CC3=C(C=C21)N=C(C4=CC=CC=C4N3C)C5=CC=C(C=C5)C(=O)O)(C)C)C
WGKドイツ
3
分子量
438.56
Reaxy-Rn
6943175
Reaxys-RN_link_address
https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=6943175&ln=

詳細データ

Taxonomic Classification

Taxonomy Tree

KingdomOrganic compounds
SuperclassOrganoheterocyclic compounds
分類Benzodiazepines
SubclassDibenzodiazepines
Intermediate Tree Nodes Not available
Direct ParentDibenzodiazepines
Alternative Parents Alkyldiarylamines  1,4-benzodiazepines  Tetralins  Benzoic acids  Benzoyl derivatives  Ketimines  Amino acids  Propargyl-type 1,3-dipolar organic compounds  Monocarboxylic acids and derivatives  Carboxylic acids  Azacyclic compounds  Organopnictogen compounds  Organooxygen compounds  Organic oxides  Hydrocarbon derivatives  
Molecular FrameworkAromatic heteropolycyclic compounds
Substituents Dibenzodiazepine - Alkyldiarylamine - 1,4-benzodiazepine - Tetralin - Benzoic acid or derivatives - Benzoic acid - Benzoyl - Tertiary aliphatic/aromatic amine - Monocyclic benzene moiety - Benzenoid - Amino acid - Ketimine - Amino acid or derivatives - Tertiary amine - Monocarboxylic acid or derivatives - Carboxylic acid - Carboxylic acid derivative - Azacycle - Organic 1,3-dipolar compound - Propargyl-type 1,3-dipolar organic compound - Organooxygen compound - Organonitrogen compound - Hydrocarbon derivative - Imine - Organopnictogen compound - Amine - Organic oxygen compound - Organic nitrogen compound - Organic oxide - Aromatic heteropolycyclic compound
説明This compound belongs to the class of organic compounds known as dibenzodiazepines. These are compounds containing a dibenzodiazepine moiety, which consists of two benzene connected by diazepine ring.
External Descriptors Not available
3 D構造
インタラクティブ化学構造モデル





関連ターゲット(人間)
RARA Tclin Retinoic acid receptor alpha (1324 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TSHR Tclin Thyroid stimulating hormone receptor (29986 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RARB Tclin Retinoic acid receptor beta (1232 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ALOX15B Tchem Arachidonate 15-lipoxygenase, type II (7244 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TP53 Tchem Cellular tumor antigen p53 (48468 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
HL-60 (67320 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
TDP1 Tchem Tyrosyl-DNA phosphodiesterase 1 (345557 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SMN1 Tchem Survival motor neuron protein (34246 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RECQL Tbio ATP-dependent DNA helicase Q1 (5575 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BLM Tchem Bloom syndrome protein (4248 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MEN1 Tchem Menin/Histone-lysine N-methyltransferase MLL (48157 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
RUNX1 Tbio Runt-related transcription factor 1/Core-binding factor subunit beta (7867 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
関連ターゲット(非人間)
Cruzipain (33337 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapk1 MAP kinase ERK2 (650 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Hdac6 Histone deacetylase 6 (222 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
lef Anthrax lethal factor (7585 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mapt Microtubule-associated protein tau (6 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Rorc Nuclear receptor ROR-gamma (89407 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FTL Ferritin light chain (43324 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
作用メカニズム
証明書(CoA、COO、BSE/TSEと分析図)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

11 results found

Lot NumberCertificate Type日付商品
C2618128C2618128Certificate of AnalysisMar 31, 2026 L287663
C23181364C23181364Certificate of AnalysisJan 19, 2026 L287663
C23181365C23181365Certificate of AnalysisJan 19, 2026 L287663
C23181377C23181377Certificate of AnalysisJan 19, 2026 L287663
C23181378C23181378Certificate of AnalysisJan 19, 2026 L287663
C23181379C23181379Certificate of AnalysisJan 19, 2026 L287663
C23181380C23181380Certificate of AnalysisJan 19, 2026 L287663
C23181381C23181381Certificate of AnalysisJan 19, 2026 L287663
C23181382C23181382Certificate of AnalysisJan 19, 2026 L287663
C23181384C23181384Certificate of AnalysisJan 19, 2026 L287663
C23181385C23181385Certificate of AnalysisJan 19, 2026 L287663
化学的性質と物理的性質
溶解度Solvent:DMSO, Max Conc. mg/mL: 43.86, Max Conc. mM: 100
分子量438.600 g/mol
XLogP37.400
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count4
Rotatable Bond Count2
Exact Mass438.231 Da
Monoisotopic Mass438.231 Da
Topological Polar Surface Area52.900 Ų
Heavy Atom Count33
Formal Charge0
Complexity778.000
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
The total count of all stereochemical bonds0
Covalently-Bonded Unit Count1
ソリューション計算機
レビュー

顧客レビュー

Application Protocols

No manufacturer-validated application protocols are provided in the Product Data for SKU L287663.

General, non-item-specific guidance for small-molecule ligands in cell-based or biochemical assays

  • Stock solution
    • Dissolve powder in anhydrous DMSO to 10–50 mM. Aliquot into amber vials; store at −20°C. Avoid repeated freeze–thaw.
  • Working solution
    • Prepare serial dilutions in DMSO, then spike into pre-warmed assay buffer/media to achieve final desired concentrations with constant vehicle (e.g., 0.1% DMSO).
    • Mix thoroughly; inspect for precipitation. Use low-binding plastics and protect from light.
  • Controls
    • Include vehicle-only negative control and, where applicable, a known agonist/antagonist as positive/orthogonal controls.
  • Readouts
    • For reporter assays, allow sufficient induction time (typically 4–24 h); for biochemical binding/enzymology, follow the kinetics appropriate to the target.
  • Data quality
    • Run in technical triplicates and biological replicates. Confirm concentration by UV/LC where feasible. Assess cytotoxicity independently to exclude confounds.

Researchers must adapt these steps to their specific systems. For any validated, product-specific protocol, refer to future updates of the CoA/Spec Sheet.

Biological Roles

Scope: The following summarizes commonly reported roles for LE 135 in research literature. These are not product-specific performance claims. For research use only.

  • General function (literature)

    • LE 135 is widely used as a small-molecule modulator of the retinoid signaling axis in biochemical and cellular studies. It serves as a reference compound in assays interrogating nuclear receptor-mediated transcription.
  • Mechanistic context (literature/generic)

    • Retinoid-pathway modulators interact with nuclear receptors that regulate gene expression via retinoic acid response elements. Antagonists are often used to suppress receptor activation by endogenous or synthetic agonists, enabling pathway mapping and target validation.
  • Typical experimental applications

    • Benchmarking antagonist potency in reporter gene assays.
    • Dissecting receptor subtype contributions by pairing with agonists/antagonists in combinatorial designs.
    • Phenotypic assays where modulation of retinoid-responsive phenotypes is probed, with appropriate counter-screens to rule out off-target or cytotoxic effects.
  • Practical considerations

    • Hydrophobic ligands can bind plastics and serum proteins; use low-binding plastics and define protein content to improve reproducibility.
    • Light sensitivity of conjugated systems suggests protecting working solutions from light to limit isomerization.
  • Data quality notes

    • Confirm compound identity and purity from CoA prior to generating dose–response curves.
    • Include orthogonal readouts where possible (e.g., transcript-level and reporter-level measures) to strengthen mechanistic inferences.
Buffer Applications

LE 135 is not a buffering reagent and is not typically used to prepare buffer systems.

Practical guidance for assay buffers (general)

  • Dissolve in DMSO to make a concentrated stock; then dilute into the assay buffer of choice (e.g., PBS, HEPES, or assay-specific media) while maintaining final DMSO at the lowest effective level compatible with the system (often ≤0.1–1% v/v).
  • If precipitation occurs upon dilution, consider:
    • Adding the stock slowly with vigorous mixing.
    • Using co-solvents within assay tolerance.
    • Adjusting pH only if compatible with biological targets and compound stability.
  • Protect diluted solutions from light; prepare fresh working solutions as needed to maintain integrity.

For actual buffer recipes, pH ranges, and ionic strengths, refer to the buffer’s own documentation; LE 135 does not provide buffering capacity.

Green Alternatives

Given LE 135 is used primarily as a bioactive reference ligand, “green alternatives” pertain more to solvent and handling choices rather than substituting the active itself.

Greener solvent strategies (general guidance)

  • Stock preparation
    • Prefer DMSO (readily recyclable, low volatility) over chlorinated solvents.
    • Use ethanol as a secondary solvent when feasible for lower concentrations, mindful of solubility limits.
  • Assay dilution
    • Keep DMSO content at the minimum effective level (≤0.1–1% v/v), balancing solubility with biological tolerance.
  • Workflows
    • Employ micro-aliquoting to reduce waste and repeated thaw cycles.
    • Use amber glass to extend solution life and reduce the need for remake, lowering solvent consumption.

Comparison (general)

  • DMSO vs DMF/NMP: DMSO typically has a better EHS profile and is widely accepted in bioassays; DMF/NMP carry higher regulatory and exposure concerns.
  • Ethanol vs acetonitrile: ethanol is bio-based and less toxic; however, acetonitrile offers superior miscibility and lower UV absorbance—choose case-by-case.

Limitations

  • Substituting the active molecule (LE 135) with a “greener” analog may not preserve biological activity; any change should be justified by SAR data. When activity is the critical output, optimize dose, solvent, and waste handling to minimize environmental footprint without compromising data quality.
Pharmaceutical Uses

This catalog item is supplied strictly for research use only; no clinical or therapeutic use is intended or implied.

Formulation-related context (general, non-clinical)

  • In preclinical research workflows, small-molecule ligands like LE 135 are often formulated for in vitro testing as DMSO stock solutions and diluted into assay media immediately before use.
  • For ex vivo or in vivo exploratory studies performed under appropriate approvals, researchers sometimes use co-solvent systems (e.g., PEG400/saline, Captisol, or Tween-80/ethanol/saline) to achieve adequate solubility; such practices must be validated independently and are not specifications of this product.

Compendial status

  • No pharmacopeial monograph information is provided for this item. Any reference to USP/EP/JP status: Not specified for this item; refer to CoA/Spec Sheet if applicable.

Manufacturing/excipient role

  • LE 135 is not an excipient; it is a bioactive research ligand. There are no item-specific data supporting use in pharmaceutical manufacturing or formulation beyond laboratory research.
Physical Properties

Item-specific specs

  • Appearance: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Melting point, boiling point, density, refractive index, UV cutoff, water/peroxide/metal levels: Not specified for this item; refer to CoA/Spec Sheet.

Literature/general expectations (verify prior to method development)

  • Many retinoid-like small molecules are solids at ambient conditions with moderate hydrophobicity and limited aqueous solubility; they are typically soluble in polar aprotic organic solvents (DMSO, DMF) and moderately soluble in ethanol.
  • A carboxylic acid functionality (reported in literature for LE-series compounds) suggests pKa in the typical aromatic carboxyl range (~4–5, literature, compound-dependent), enabling pH-dependent solubility enhancement as the carboxylate salt in basic media.
  • LogP/logD values for retinoid scaffolds are often high (literature: hydrophobic), which informs formulation and membrane-partitioning behavior in bioassays.

Practical notes (general)

  • Prepare concentrated DMSO stocks (e.g., 10–50 mM) and dilute into assay buffer with vigorous mixing to minimize precipitation. Include carrier protein (e.g., 0.1% BSA) or co-solvent (≤0.5–1% DMSO v/v) as assay-tolerated.
  • Protect from strong light to mitigate potential photoisomerization of conjugated systems (general retinoid handling best practice). Always confirm item-specific stability from the CoA/SDS.
Quality and Grades
  • Item-specific grade (from Product Data): Moligand™

    • Moligand™ indicates suitability for use as a small-molecule ligand in screening and discovery workflows (e.g., target/phenotypic assays), emphasizing identity and purity control tailored for bioassay compatibility rather than process-scale manufacturing.
  • What this typically means (general guidance; check CoA for specifics)

    • Identity verification by orthogonal methods (e.g., NMR/HRMS/UPLC) to support reproducible biological readouts.
    • Purity typically optimized for cell-free/cellular assays; low-level inorganic residues and nonvolatile impurities are minimized to reduce assay interference. Exact purity percent and impurity profile: Not specified for this item; refer to CoA/Spec Sheet.
    • Solvent residue limits and light/thermal stability controls are usually part of release testing for retinoid-like ligands; actual limits: Not specified for this item; refer to CoA/Spec Sheet.
  • Stabilizers/additives

    • No stabilizer information is listed in the Product Data. If stabilizers or formulating agents are used (e.g., antioxidants), they will be declared on the CoA/SDS. Current item-specific status: Not specified for this item; refer to CoA/Spec Sheet.
  • Fit-for-purpose notes

    • For medicinal chemistry, chemical biology, and screening teams, Moligand™-grade material is intended to provide reliable on-target signal with controlled background. For analytical chromatography or GMP manufacturing, select grades explicitly qualified for those applications and verify additional specs as required.
Reaction and Applications

This product is primarily a bioactive small-molecule ligand for research assays and screening, not a general-purpose synthetic reagent. Consequently, classic synthetic reaction applications (e.g., cross-couplings, Grignard, oxidations) are not the typical use case for LE 135.

  • Not typically applicable

    • No manufacturer-specified roles as a catalyst, reagent, or building block are provided.
    • There are no item-specific recommendations for use in stoichiometric or catalytic transformations.
  • Where it is relevant (general, literature)

    • Employed as a reference modulator in retinoid-receptor pathway investigations in biochemical and cell-based assays, often to benchmark antagonist/agonist responses.
    • Utilized in target deconvolution or phenotypic screens as a comparator control.
  • Practical notes for assay applications (general)

    • Prepare fresh DMSO stocks, protect from light, aliquot, and avoid repeated freeze–thaw to preserve potency.
    • Validate concentration–response curves across an appropriate dilution range; confirm solubility limits to prevent colloid formation.
    • Include counter-screens (e.g., reporter-free viability) to exclude nonspecific assay interference.

If you require a synthetic building block related to this scaffold (e.g., for SAR elaboration), consider ordering intermediate analogs with declared functional handles; this listing is intended for bioactivity studies rather than preparative chemistry.

Reaction Conditions

Classical synthetic “reaction conditions” (solvent, catalysts, temperatures, yields) are not typically applicable to LE 135 as sold, because it is intended for use as a bioactive reference ligand rather than as a reagent or substrate.

General handling conditions for bioassays (practical, non-item-specific)

  • Stock preparation: dissolve in dry DMSO at 10–50 mM; vortex and sonicate briefly if needed. Filter (0.2 µm PTFE) only if compatible.
  • Working concentrations: determine empirically via concentration–response studies; include vehicle controls matched for DMSO content.
  • Temperature and light: handle at room temperature during assay setup; protect from light (amber tubes) to limit photoisomerization.
  • Incubation times: dictated by assay format (e.g., 4–24 h for transcriptional reporter assays); validate for your system.

If you require chemical transformation conditions for scaffold synthesis or analog preparation, consult the primary literature on retinoid-mimetic synthesis (e.g., Wittig/HWE olefinations, Pd-catalyzed couplings). Such conditions are outside the scope of this catalog item.

Safety and Handling

Item-specific hazard details

  • GHS Classification: Not specified for this item; refer to SDS.
  • Signal Word / Pictograms / H-statements: Not specified for this item; refer to SDS.

General laboratory precautions (for small-molecule screening ligands)

  • PPE: laboratory coat, nitrile gloves, and safety glasses; handle powders/solids in a fume hood to avoid inhalation exposure.
  • Avoid ingestion, inhalation of dust/vapors, and skin/eye contact. Wash thoroughly after handling. Decontaminate surfaces with appropriate organic-solvent-compatible wipes.
  • Incompatibilities: strong oxidizers and strong bases/acids may degrade retinoid-like frameworks; avoid prolonged exposure to light and elevated temperatures.
  • First aid (overview; defer to SDS):
    • Inhalation: move to fresh air; seek medical attention if symptoms persist.
    • Skin/eye contact: rinse with water for several minutes; remove contaminated clothing; get medical advice for persistent irritation.
    • Ingestion: rinse mouth; do not induce vomiting; seek medical attention.

Special risks and handling advice (general, literature-based for conjugated/aromatic acids)

  • Light sensitivity: protect from light (amber vials/foil) during storage and handling to limit photoisomerization or degradation.
  • Stock solutions: prepare in dry, high-purity DMSO; aliquot to single-use vials to minimize freeze–thaw and headspace oxygen exposure.
  • Waste: collect organic waste according to institutional and local regulations; do not discharge to drains.

Authoritative source: Always consult the product-specific SDS and CoA for definitive safety, hazard, and disposal guidance.

Solvent Selection

Context: LE 135 is supplied as a research ligand. No item-specific solubility data are provided; the guidance below reflects general practice for hydrophobic, retinoid-like small molecules.

  • Polarity class (general): hydrophobic/weakly polar with an ionizable acid group (if present); shows strong affinity for polar aprotic solvents.
  • Recommended stock-solvent choices
    • DMSO (anhydrous, ≥99.9%): primary choice for concentrated stocks (e.g., 10–50 mM); excellent solvating power for aromatic, conjugated scaffolds.
    • DMF or NMP: alternatives when DMSO is contraindicated; verify assay tolerance and material compatibility.
    • Ethanol (absolute) or methanol: for lower-concentration stocks; watch for precipitation upon aqueous dilution.
  • Aqueous use
    • Direct dissolution in water/buffer is typically poor for retinoid-like acids at neutral pH; dissolve in DMSO then dilute into buffer. If a carboxylic acid is present, limited pH-driven solubility enhancement may occur above pKa; confirm stability of the conjugated system in basic media.
  • Miscibility and co-solvent strategies
    • Maintain final DMSO ≤0.1–1% v/v in biochemical or cell assays, as tolerated.
    • Use carrier proteins (e.g., 0.1% BSA) or non-ionic surfactants (e.g., 0.01–0.05% Tween-20) for challenging dilutions, after validating assay compatibility.

Comparison (general)

  • DMSO vs ethanol: DMSO affords higher stock concentrations and less evaporation; ethanol offers faster drying in coating/immobilization workflows but lower solubility for hydrophobic ligands.
  • DMF vs DMSO: similar solvency; DMF is more hygroscopic and can be less tolerated biologically; choose DMSO when possible.
Storage and Reconstitution

Item-specific conditions (from Product Data)

  • Storage: Store at −20°C.
  • Shipping: Ice chest + ice pads.

General best practices for this compound class

  • Light protection: Store in amber glass or foil-wrapped containers to limit photo-degradation of conjugated systems.
  • Atmosphere: Keep containers tightly closed; minimize headspace. If feasible, flush with inert gas during long-term storage of solids or high-concentration solutions.
  • Solid stability: Keep desiccated and at −20°C. Avoid repeated warming–cooling cycles.

Reconstitution guidance (general; not a specification)

  • Preferred solvent: DMSO (anhydrous).
  • Typical stock concentration: 10–50 mM, depending on solubility; verify visually and, if critical, analytically (e.g., LC).
  • Aliquoting: Prepare single-use aliquots (e.g., 10–50 µL) to avoid freeze–thaw.
  • Working solution: Dilute into buffer/media immediately before use; maintain consistent vehicle percentage across samples.
  • Freeze–thaw: Avoid; if unavoidable, limit to ≤2–3 cycles and monitor for precipitation or activity loss.

Expiration and specifications

  • Retest/expiration date, exact solubility, and stability-in-solution: Not specified for this item; refer to CoA/Spec Sheet and SDS for definitive guidance.

For research use only.

Structure and Identity

Brief overview: LE 135 is supplied as a Moligand-class small molecule for research screening. Detailed structural identifiers are not provided in the item’s Product Data; consult CoA/Spec Sheet for definitive identifiers.

  • Item-specific (from Product Data)

    • SKU: L287663
    • CAS: 155877-83-1
    • Grade: Moligand™
    • InChIKey: Not specified for this item; refer to CoA/Spec Sheet. (Note: the short code “451360” in Product Data is not a valid InChIKey.)
    • SMILES: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
    • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • Literature/general chemistry (for context; verify against CoA before use)

    • LE 135 is widely cited as a synthetic retinoid-pathway modulator used as a reference antagonist in receptor biology studies.
    • Reported structures in literature describe an aromatic polyene/retinoid-like scaffold bearing a carboxylic acid functionality; exact stereochemistry and substitution pattern should be confirmed from the authoritative CoA/SDS for this catalog item.
  • Structural features (general description based on literature)

    • Functional groups often include: aromatic rings and a carboxylic acid; conjugated double-bond system typical of retinoid mimetics.
    • No item-specific stereochemical assignment is provided in Product Data.
  • 2D structural description in words (general, literature): a conjugated aryl–alkenyl framework terminating in a benzoic or pyridyl carboxylate motif is commonly depicted for LE-series retinoid modulators; confirm exact ring system and substitution from CoA.

Synthetic Utility

LE 135 is offered as a bioactive ligand for screening and mechanism studies rather than as a synthetic intermediate. Therefore, its direct utility as a building block is limited.

  • Not typically used as a reagent

    • No manufacturer data indicate functional handles or protected groups intended for downstream derivatization.
  • General retrosynthetic perspective (literature-based, conceptual)

    • Retinoid-like scaffolds are commonly assembled via cross-coupling or olefination strategies (e.g., Wittig, Horner–Wadsworth–Emmons, Heck/Suzuki) to construct conjugated aryl–alkenyl motifs, followed by introduction or adjustment of a carboxylic acid function when present.
    • Structure–activity relationship (SAR) studies around such scaffolds often vary aryl substitution, linker geometry (E/Z control), and terminal acidic groups to tune receptor interactions and physicochemical properties.
  • If derivatization is desired

    • Consider purchasing analogs or precursors with explicit synthetic handles (e.g., bromo/iodo aryl, boronate, alkyne/alkene) rather than modifying the bioactive reference compound itself.
    • When purity and identity of the parent reference standard are critical for biology, avoid chemical modification that could confound interpretation.

Conclusion: Treat LE 135 primarily as a reference ligand rather than a synthetic synthon; use it to benchmark biological responses and reserve synthetic campaigns for separately sourced, purpose-designed intermediates.

Target Specificity

Only product-data-sourced target attributes may be listed here. For this item:

  • Target/Pathway: Not specified for this item; refer to CoA/Spec Sheet.
  • Species reactivity: Not specified for this item; refer to CoA/Spec Sheet.
  • Mode of action (agonist/antagonist, etc.): Not specified for this item; refer to CoA/Spec Sheet.
  • Assay validation notes: Not specified for this item; refer to CoA/Spec Sheet.

Note: While the literature discusses LE 135 as a retinoid-pathway modulator, Aladdin provides no item-specific target certification in the Product Data. Users should perform their own target validation under their assay conditions.

よくある質問

What is the purity of this product, and how is it determined?
This product is supplied at ≥97% purity, determined by HPLC. Lot-specific values are stated on the Certificate of Analysis.
What is Moligand??
Moligand? is one of Aladdin Scientific's premium product lines, formulated for high-purity applications across multiple workflows. Compared to standard grades in the same workflow, Moligand? products typically offer tighter specifications, more rigorous QC, and stronger lot-to-lot consistency.
How should this product be stored?
Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.
How is this product shipped?
This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.
What are the CAS number, molecular formula and molecular weight?
The CAS Number is 155877-83-1, the molecular formula is C29H30N2O2, and the molecular weight is 438.56 g/mol. InChIKey YZZAIQOVMHVWBS-UHFFFAOYSA-N.
What documentation is provided?
Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.